Sanofi Press Release: Sanofi’s AMETHIST trial for GM2 gangliosidosis discontinued

Today it was announced by Sanofi that the AMETHIST phase 3 study of venglustat for the treatment of GM2 gangliosidosis was discontinued based on the absence of positive trends on clinical endpoints.

This is incredibly disappointing news as we had hoped it would potentially provide a much needed treatment option for our community.

We are working with our advocacy partners NTSAD and the Cure GM1 Foundation to explore next steps and we will provide more details on this in the coming weeks when it is available.

The full press release can be read here.

Please know that this disappointment will not stop the work we are all doing to support our communities and we will continue to explore potential future treatments.

If you have any questions please reach out to us.